https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-01721&r=1
Revumenib and Venetoclax for the Treatment of Patients with Acute Myeloid Leukemia with Measurable...
Revumenib and Venetoclax for the Treatment of Patients with Acute Myeloid Leukemia with Measurable Residual Disease
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-06738
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant - NCI
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-10509
Revumenib, Azacitidine, and Venetoclax for the Treatment of Pediatric and Young Adult Patients with...
Revumenib, Azacitidine, and Venetoclax for the Treatment of Pediatric and Young Adult Patients with Refractory or Relapsed Acute Myeloid Leukemia or Acute...
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT05326516&r=1
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia - NCI
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2026-00501
Revumenib and Mezigdomide for the Treatment of Relapsed or Refractory KMT2A-Rearranged,...
Revumenib and Mezigdomide for the Treatment of Relapsed or Refractory KMT2A-Rearranged, NPM1-Mutant, and NUP98-Rearranged Acute Leukemias
for the
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2019-07963
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1...
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
https://adisinsight.springer.com/trials/700391169?error=cookies_not_supported&code=6edfc0f4-190e-447c-baab-955a47983d33
A Phase 2 collaborative trial of revumenib in combination with venetoclax and azacitidine in newly...
A Phase 2 collaborative trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed KMT2Ar patients who would be considered eligible,
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation
FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation | FDA
On November 15, 2024, the Food and Drug Administration approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or...